Done Deal: Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of New Phase 2-ready AD Treatment
Johnson & Johnson completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody targeting two pathways in atopic dermatitis (AD). The deal was an all-cash transaction of approximately $1.25 billion. NM26, which is ready to enter Phase 2 studies in […]